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Essentials
• AFSTYLA exhibits %50% underestimation in activity when the one-stage (OS) assay is utilized.
• A field study compared the performance of AFSTYLA with Advate in factor VIII activity assays.
• AFSTYLA activity can be monitored with both the chromogenic substrate and the OS assay.
• The consistent OS underestimation allows for a conversion factor to be applied to OS results.
Summary. Introduction: AFSTYLA (antihemophilic factor
[recombinant] single chain) is a novel B-domain truncated recombinant factor VIII (rFVIII). For AFSTYLA, an approximate 50% discrepancy was observed between results of the one-stage (OS) and chromogenic substrate (ChS) FVIII activity assays. An investigation was undertaken to test whether there is a linear relationship between ChS and OS assay results that would allow reliable clinical interpretation of results independent of the assay method used. Aims: To provide confidence in future clinical monitoring, this field study investigated the performance of AFSTYLA and a full-length rFVIII (Advate Ò ) in FVIII activity assays routinely performed in clinical laboratories. Methods: The comparison of AFSTYLA and Advate was performed in an international, multicenter and blinded field study of simulated post-infusion samples. The study documented the extent of variability between methods and laboratories and characterized the relationship between the ChS and OS assays. Results: Results from 23 laboratories demonstrate that intra and interlaboratory variability in OS assays were similar for both products. When comparing within the OS assay format, there was a similar and reagent-correlated variability in response to different activators for both AFSTYLA and Advate. The OS underestimation was highly predictable and consistent across the complete range of FVIII plasma concentrations. Conclusion: Postinfusion plasma AFSTYLA levels can be monitored in patients by the OS and ChS assays. The consistent andIntroduction AFSTYLA is a novel, recombinant FVIII (rFVIII) in which the heavy and light chains are covalently fused to achieve a single polypeptide protein. Upon activation by thrombin, AFSTYLA is structurally and functionally indistinguishable from endogenous, activated FVIII [1, 2] . During development of AFSTYLA, an approximate 50% discrepancy was observed between the one-stage (OS) and chromogenic substrate (ChS) assays. Preclinical animal studies and biochemical characterization studies demonstrated that the ChS assay reflected the expected clinical effectiveness of AFSTYLA and therefore was used for potency assignment upon drug product release. The efficacy results of a large pivotal clinical study [3] confirmed that the ChS assay most accurately reflects the clinical hemostatic potential of AFSTYLA.
The discrepancy between the ChS and OS assays is not unique to AFSTYLA; full-length recombinant products report FVIII activity measurements that are 20% lower with the OS assay compared with the ChS assay, and B-domain deleted or truncated products report discrepancies between 20% and 50% [4] [5] [6] [7] [8] . Despite these discrepancies, most of the recently approved rFVIII products on the market support both ChS and OS monitoring without scientific guidance for physicians on how to correct for the differences between the two assay methods.
Although the ChS assay is used for potency assignment of AFSTYLA, the OS assay remains the predominant method in clinical testing. Given the difference between the two assay methods, it was important to provide appropriate guidance to clinicians using the OS method. In order to characterize the relationship and allow for a comprehensive assessment between the two assays, the AFSTYLA clinical development program was designed to determine FVIII activity utilizing both methods. PK samples obtained during the pivotal clinical study revealed a linear relationship between OS and ChS assay results and a single conversion factor of 1.8 applied to OS measurements aligned the results of the two assay methods [3] . Recognizing that in clinical practice variability estimates can differ from laboratory to laboratory and reagent to reagent, CSL Behring initiated a field study in order to ensure the feasibility of using a single conversion factor.
This field study was designed to determine the variability observed when measuring AFSTYLA, using a range of assay reagents and formats routinely used by clinical monitoring laboratories and compare it with the variability observed when measuring a widely available rFVIII product (Advate). Additionally, the field study was designed to determine whether the consistent relationship observed by CSL Behring between the OS and ChS methods would be maintained in routine clinical laboratory testing.
Methods

Participating centers
Twenty-eight laboratories worldwide agreed to participate and received field study kits. Of those, 23 laboratories (13 from the USA, eight from the EU, one from Canada and one from South Africa) completed data entry prior to final analysis.
Field study kit FVIII-immunodepleted plasma (Siemens Healthineers, Marburg, Germany) samples were spiked at 0.04, 0.3, 0.6 and 1.0 IU mL À1 for both AFSTYLA (based on the chromogenic-labeled potency) and Advate (based on the nominal FVIII potency), blinded, and distributed to participating laboratories to be assayed by the OS and ChS FVIII assays. Each kit contained 30 vials, three aliquots of each spiked plasma sample (Samples A-H, 1.0 mL plasma/aliquot), three vials of Standard Human Plasma (SHPL) (Sample J), lyophilized, to be reconstituted in 1 mL water, and three vials of Product Specific Reference Standard (Sample K), lyophilized, to be reconstituted in 1 mL water. Sample J and Sample K were supplied for an optional analysis in order to allow for recalculation of results against a common standard; data for the reference standards J and K are not presented in this manuscript. This analysis was not performed, as adjustment of reportable factor assay data by the ratio of a clinical laboratory's accuracy in assessing the content of an external control is not performed in routine clinical practice. Upon receipt, samples were to be stored at À70°C until the day of assay. If the samples arrived thawed, sites were directed to discard them and request new aliquots.
Testing
Sites were instructed to assay samples on three separate days with no more than 15 days separating the first and third run. Participating laboratories followed their routine laboratory practices. All laboratories performed FVIII activity assays on provided materials using standard reagents and instrumentation that were employed routinely for FVIII activity measurement in their clinical hemostasis laboratories. The samples were assayed using the laboratories internal in-house standard for calibration. Laboratories evaluated the samples using either an OS assay or a ChS assay, depending on local clinical practice (or both if routinely used in the laboratory).
Data collection
Laboratories provided raw data as coagulation time or extinction (electronically) and the calculated FVIII activity from the internal in-house standard. Completed data collection forms were to be retained by the laboratory. Participating laboratories reported results with varying unitage (such as IU dL À1 , IU mL À1 and %); for the purposes of this field study, given the intrinsic imprecision of the OS assay and in order to emulate how clinicians translate data from research publications into their clinical practice, these unitages were taken to be similar. 
Results
Assays used
A variety of OS assay formats were used by the 23 laboratories. The OS clotting assay was performed by all 23 laboratories and the ChS assay was additionally performed by six of the 23 laboratories (two in the USA).
Instruments and reagents used for each laboratory are listed in Table S1 . Nine laboratories used assays with silica as activator, three used assays with silicon dioxide particles, one an assay with kaolin and 10 used an assay with ellagic acid as activator (Table S1 ). An effect of the type of activator used on the observed concentrations of AFSTYLA or Advate was not apparent.
One-stage assay
Observed concentrations (represented as % of normal human plasma [NHP]) are summarized in Fig. 1 (A-D).
As expected, OS concentrations were consistently lower than the targeted spike concentration across the full range of spiked samples for AFSTYLA (Table 1A) . Advate concentrations were consistently higher than the targeted spike concentrations. In general, laboratories that yielded high results for Advate also yielded proportionally higher results for AFSTYLA, and laboratories that yielded relatively low results for Advate did the same for AFSTYLA. Overall assay precision estimates are summarized in Table 2A . The assay variability was comparable for AFSTYLA and Advate at all spike levels. Interlaboratory % CV ranged from 17% to 29% for AFSTYLA and 14% to 35% for Advate, which is also aligned with the interlaboratory % CV published for other rFVIII products (Table 2B ). Variability was highest for both products at the lowest concentration and essentially constant at concentrations ≥ 30% for both products.
Accuracy was assessed for both AFSTYLA and Advate. The percent accuracy was calculated as = 100 9 (observed concentration/expected concentration), where the observed concentration is the interpolated concentration entered by the laboratory and the expected concentration is the targeted spiking concentration. Percent accuracy ranged from 34% to 117% for AFSTYLA and 23% to 308% for Advate. This is illustrated in Fig. 2 
(A-D).
Chromogenic substrate assay A total of six laboratories performed the FVIII ChS assay. Observed results (represented as % of NHP) are summarized in Fig. 3 (A-D) . As expected, measured chromogenic concentrations were near the targeted spike concentration for the full range of spiked samples for AFSTYLA. Accuracy was assessed for both AFSTYLA and Advate. The percent accuracy was calculated as = 100 9 (observed concentration/expected concentration), where the observed concentration is the interpolated concentration entered by the laboratory and the expected concentration is the targeted spiking concentration. Across all spikes, the accuracy of AFSTYLA measurements ranged from 104 to 168% and from 101 to 186% for Advate (Fig. 4A-D) . As expected, measurements of spikes with the lowest concentrations of AFSTYLA and Advate (0.04 IU mL À1 ) yielded the lowest accuracy (168% for AFSTYLA and 186% for Advate).
Overall assay precision estimates are summarized in Table 2A . The assay variability was comparable for AFSTYLA and Advate. Variability estimates were significantly lower for the ChS assay for both AFSTYLA and Advate compared with the OS assay. Interlaboratory % CV for the ChS assay ranged from 4% to 16% for AFSTYLA and 4% to 20% for Advate; variability was highest for both products at the lowest concentration.
Comparison between the OS and ChS assays for the purpose of establishing a conversion factor
The ChS/OS relationship for AFSTYLA is highly consistent across a range of laboratories that have established the ChS assay in their routine clinical practice (Table 1) , meaning a conversion can be utilized to align the OS and ChS measurements. As shown in Table 1 , when only accounting for the laboratories that have established both the OS and ChS methods, a mean ratio of 1.8 was found across all spiked concentrations, the same ratio that was observed in the PK investigation conducted by CSL Behring. When all OS measurements were taken into account, ratios of 1.8-2 were observed across the different spiked concentrations.
OS correction with a conversion factor The majority of the 'corrected' AFSTYLA results are within an acceptable range [9] around the target value (20% variability estimates AE 2 SD), and the distribution was comparable to Advate results obtained with the OS assay. Ten of the 23 laboratories measuring Advate were beyond the 20% variability estimates AE 2 SD accuracy range for the 0.04 IU mL À1 spike, whereas only eight of 23 were beyond for AFSTYLA (five out of eight of those laboratories were also out of range for Advate) when using a conversion factor of 1.8. For the 0.3 IU mL À1 spike, eight of 23 laboratories measuring
Advate were beyond the 20% variability estimates AE 2 SD accuracy range, whereas only two of 23 were beyond for AFSTYLA (both of those laboratories were also out of range for Advate). Similarly, for the 0.6 IU mL À1 spike, six of 23 laboratories measuring Advate were beyond the 20% variability estimates AE 2 SD accuracy range, whereas none were beyond for AFSTYLA. For the 1.0 IU mL À1 spike, two of 23 laboratories measuring
Advate were beyond the accuracy range, whereas none were beyond for AFSTYLA. When using a conversion factor of 2, 11 of 23 laboratories measuring AFSTYLA were beyond the 20% variability estimates AE 2 SD accuracy range for the 0.04 IU mL À1 spike (six out of 11 of those laboratories were also out of range for Advate). For the 0.3 IU mL À1 spike, five of 23 laboratories measuring AFSTYLA were beyond the 20% variability estimates AE 2 SD accuracy range (three out of five of those laboratories were also out of range for Advate). Similarly, for the 0.6 IU mL À1 spike, two of 23
were beyond for AFSTYLA (none of those out of range for Advate). And for the 1.0 IU mL À1 spike, two of 23 laboratories measuring AFSTYLA were beyond the accuracy range (none of those out of range for Advate).
Discussion
This international, multicenter and blinded field study investigated the performance of AFSTYLA and Advate in FVIII activity assays routinely run in clinical laboratories. The comparison of AFSTYLA and Advate was performed in simulated post-infusion samples. Similarly designed field studies have been executed in the past for other new rFVIII products [5] [6] [7] [8] . This study included 28 laboratories in seven countries in three continents with complete data from 82% of the participating laboratories (with 23 laboratories providing OS data and six laboratories providing ChS data), ensuring the robustness of the conclusions derived from this dataset and avoiding potential reporting bias. The utilization of the ChS assay is increasing, and more than 80% of US Hemophilia Treatment Centers (HTCs) have the ChS assay available for patients if needed, either in hospital or by using external service providers (data on file). Published literature supports the view that the ChS assay most accurately reflects the therapeutic effect of rFVIII [4] . The pivotal clinical trial of AFSTYLA clinically verified that the potency assigned by the ChS assay resulted in the expected clinical efficacy with dosing according to World Federation of Hemophilia guidelines [3] . This field study demonstrated that variability estimates were significantly lower for the ChS assay for both AFSTYLA and Advate compared with the OS assay. In addition, ChS values were near target at all spiked levels when laboratories utilized the ChS assay. Although the OS method remains the dominant assay format for the assessment of FVIII activity in human plasma, the method has several limitations. Differentiation of two limitations in particular is often blurred; however, to fully characterize the performance of rFVIII in this assay format one must examine them independently in order to present a clear picture. First, the underestimation of FVIII:C levels compared with the ChS assay: traditional activated partial thromboplastin time (APTT)-based OS methods usually yield results that are 20-50% lower than those obtained by ChS assays [4] . The discrepancy is well recognized and widely reported for most recombinant factor VIII concentrates [5] [6] [7] . Second, the high degree of variation across OS reagents: healthcare professionals treating patients with hemophilia are left to contend with as much as a 40% variation across the different OS reagents, yet a certain degree of variability (up to 20%) is tolerated in clinical monitoring [10] . Peyvandi et al. pointed out that an acceptable clinical interpretation of the FVIII activity of products with systematic discrepancies across reagents may be possible if these discrepancies are well characterized and if a correction factor can be applied according to the manufacturer's guidelines [10] . The authors stated that the feasibility of such an approach would be dependent on two things: the OS underestimation being predictable across the entire range of FVIII activity values observed in clinical practice and the variability being consistent with that of other full-length products [10] . Although variability estimates for other recently approved products remain fairly consistent (Table 2B ), a concentration-dependent discrepancy of approximately 20-30% between the ChS and the OS assays exists, which does not allow for a single conversion factor (Table 1B) .
Results of this field study confirmed the consistent underestimation of OS values compared with the ChS assay across the range of spiked samples and laboratories, allowing an opportunity to correct the difference. Despite the array of reagents and instruments used by the participating laboratories, the precision was comparable for AFSTYLA and Advate using the OS clotting assay. Interlaboratory % CV ranged from 17% to 29% for AFSTYLA and 14% to 35% for Advate, where variability was highest for both products at the lowest concentration (increased imprecision of the OS clotting assay at low levels of FVIII is well described in the medical literature [11] ). For AFSTYLA, the results of this field study confirmed a systematic underestimation of OS activity measurements across different spiked concentrations with all APTT reagents compared with Advate. The comparable variability, the consistent ChS/OS ratio and the systematic underestimation of OS activity measurements across different spiked concentrations, confirms the reliability of utilizing a single conversion factor. Multiplication of results obtained by the OS assay by a conversion factor aligned FVIII activity measurements of AFSTYLA with the target concentration with an accuracy that is comparable with Advate's drug profile. When comparing the accuracy for AFSTYLA results (with a conversion factor applied) with the results of other field studies, the accuracy of AFSTYLA is comparable to, or better than, that achieved with the OS assay for other recently approved rFVIII products (Table 3) .
This field study has several methodological limitations. By definition, conclusions of a field study are limited by the reagents studied, and further generalization is, to some extent, an extrapolation. The cohort of laboratories that participated in this project was somewhat smaller than that included in some of the previously reported field studies of engineered factor replacement therapies. Only six APTT reagents were being utilized by the participant laboratories and only a single laboratory reported data based upon a kaolin activator, compared with up to 35 laboratories and up to 15 APTT reagents in the large study of Adynovate (although the authors of that study acknowledge that redundancy could not be excluded in their international study because reagents are potentially marketed under different brand names) [6] . Thus, although a consistent trend between AFSTYLA and Advate was observed for the reagent combinations utilized by the laboratories participating in this study, clinical laboratories may want to verify the findings of this field trial using the reagents they currently deploy. Similar to other field studies, laboratories provided data for the one lot of reagent that was in use at the time they participated in the field study; no participant tested the consistency of reagents' performance between multiple lots of reagent obtained from a given manufacturer. Likewise, a single lot of AFSTYLA was utilized and spiked samples were prepared using a single lot of immunodepleted plasma.
As the OS assay remains the method of choice for routine clinical monitoring in a number of countries, including the USA, clinicians need manufacturer-guided options to convert inaccurate OS assay results [10] , and for AFSTYLA, the conversion factor provides an appropriate solution. The clinical acceptance of 20% variation in the OS assay allows for fluctuations in the conversion factor. Although a consistent ratio of 1.8 was observed for laboratories utilizing both the OS and ChS assays, which most closely aligned OS assay results to target, we appreciate the simplicity of using a whole integer as the conversion factor. Multiplication of results obtained by the OS assay by 2 aligns FVIII activity measurements of AFSTYLA with targeted spike concentrations with an accuracy that is comparable with Advate's drug profile. Given the novelty of the conversion factor in a clinical setting where multiple coagulation factors are in use, excellent communication and awareness when interpreting laboratory monitoring results of patients treated with AFSTYLA are mandatory to avoid misinterpretation of assay findings.
Conclusion
Despite the methodological variations that have been observed in laboratory assays, these data demonstrate that post-infusion plasma AFSTYLA levels can be safely monitored in patients by either the OS or ChS assay. The consistent and predictable difference between the two assay formats, across laboratories and FVIII plasma concentrations, enables physicians to apply a conversion factor of 2 to OS assay results, which allows for interpretation of AFSTYLA measurements obtained with the one-stage assay with a degree of accuracy that has been accepted and safely used for other rFVIII products for decades. Friedman contributed to the design of the study and analysis and interpretation of data, drafted the manuscript, and reviewed and approved the final version. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
